Favrille Announces Receipt of Nasdaq Letter
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the developmentand commercialization of targeted immunotherapies for the treatment of cancerand other diseases of the immune system.
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Favrille's listing or delisting from theNasdaq Global Market, any appeal of the Nasdaq delisting determination, thetrading of Favrille's common stock on the OTC Bulletin Boards or the "PinkSheets," Favrille's product candidates, proprietary technologies and researchand clinical development programs. Such forward-looking statements involveknown and unknown risks, uncertainties and other factors that may causeFavrille's actual results to be materially different from historical resultsor from any results expressed or implied by such forward-looking statements.These factors include, but are not limited to, risks and uncertainties relatedto Favrille's listing status and potential delisting of Favrille's commonstock from The Nasdaq Global Market, the possibility that no market maker willseek to register in and quote Favrille's common stock on the OTC BulletinBoards or the "Pink Sheets," Favrille's ability to continue its operations,conserve cash or recognize value on its assets and additional risks discussedin Favrille's filings with the Securities and Exchange Commission. Allforward-looking statements are qualified in their entirety by this cautionarystatement. Favrille is providing this information as of the date of thisrelease and, except as required by law, does not undertake any obligation toupdate any forward-looking statements contained in this release as a result ofnew information, future events or otherwise.
SOURCE Favrille, Inc.
You May Also Like